tak-475 and Dyslipidemias

A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide another therapeutic option for clinicians to improve risk management of low-density lipoprotein cholesterol (LDL-C). The clinical need for another LDL-C-lowering therapy is evident by the inability to achieve an LDL-C target of less than 70 mg/dL in the majority of very high-risk patients on statin monotherapy. Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published.

Topics: Clinical Trials, Phase III as Topic; Drug Delivery Systems; Dyslipidemias; Farnesyl-Diphosphate Farnesyltransferase; Humans; Oxazepines; Piperidines